Federico Rojo

MET phosphorylation predicts poor outcome in small cell lung carcinoma and its inhibition blocks HGF-induced effects in MET mutant cell lines

S. Serrano, M. Salido, F. Hirsch, 2011, British Journal of Cancer.

PP2A inhibition determines poor outcome and doxorubicin resistance in early breast cancer and its activation shows promising therapeutic effects

J. Albanell, J. Madoz-Gúrpide, O. Arpí, 2015, Oncotarget.

DUSP1/MKP1 promotes angiogenesis, invasion and metastasis in non-small-cell lung cancer

A Rovira, F. Rojo, J. Albanell, 2011, Oncogene.

Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology

F. Rojo, J. Albanell, M. Martín, 2017, Clinical and Translational Oncology.

Presence of rare potential pathogenic variants in subjects under 65 years old with very severe or fatal COVID-19

Maximiliano García Torrejón, I. Mahillo, F. Rojo, 2022, Scientific Reports.

Edinburgh Research Explorer Effect of MAF amplification on treatment outcomes with adjuvant zoledronic acid in early breast cancer: a secondary analysis of the international, open-label, randomised, controlled, phase 3 AZURE (BIG 01/04) trial

J. Albanell, J. Tercero, Roger R. Gomis, 2018 .

NK cell-triggered CCL5/IFNγ-CXCL9/10 axis underlies the clinical efficacy of neoadjuvant anti-HER2 antibodies in breast cancer

L. Comerma, S. Servitja, O. Arpí, 2024, Journal of experimental & clinical cancer research : CR.